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Maturation of West Nile Virus Modulates Sensitivity to
Antibody-Mediated Neutralization
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Abstract
West Nile virions incorporate 180 envelope (E) proteins that orchestrate the process of virus entry and are the primary target
of neutralizing antibodies. The E proteins of newly synthesized West Nile virus (WNV) are organized into trimeric spikes
composed of pre-membrane (prM) and E protein heterodimers. During egress, immature virions undergo a proteasemediated cleavage of prM that results in a reorganization of E protein into the pseudo-icosahedral arrangement
characteristic of mature virions. While cleavage of prM is a required step in the virus life cycle, complete maturation is not
required for infectivity and infectious virions may be heterogeneous with respect to the extent of prM cleavage. In this
study, we demonstrate that virion maturation impacts the sensitivity of WNV to antibody-mediated neutralization.
Complete maturation results in a significant reduction in sensitivity to neutralization by antibodies specific for poorly
accessible epitopes that comprise a major component of the human antibody response following WNV infection or
vaccination. This reduction in neutralization sensitivity reflects a decrease in the accessibility of epitopes on virions to levels
that fall below a threshold required for neutralization. Thus, in addition to a role in facilitating viral entry, changes in E
protein arrangement associated with maturation modulate neutralization sensitivity and introduce an additional layer of
complexity into humoral immunity against WNV.
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(prM), and capsid (C)), a lipid envelope, and an ,11 kilobase
monocistronic RNA of positive-sense polarity [1]. Crystal
structures of the E protein of several related flaviviruses (WNV,
dengue virus (DENV), tick-borne encephalitis virus (TBE)) reveal
an organization of three domains connected by flexible hinges
(reviewed in [4]). Domain III (DIII) is an immunoglobulin-like fold
that is thought to participate in interactions between virions and
cellular factors associated with virus entry. Domain II (DII) is a
long, finger-like domain that contains a stretch of 13 conserved,
hydrophobic residues that form an internal fusion loop. DIII
and DII are linked together by a b-barrel structure that
comprises domain I (DI). The structure of prM, which forms
heterodimers with the E protein during virion biogenesis, is
presently unknown.
Flaviviruses assemble at the endoplasmic reticulum (ER) and
bud into the lumen as immature virus particles [5]. Cryoelectron
microscopic reconstructions of immature virions reveal an
icosahedral arrangement of 60 trimeric spikes composed of prM:E
heterodimers in which the prM protein is positioned to cover the
fusion peptide located at the distal end of each E protein of the

Introduction
Flaviviruses are a group of positive-stranded RNA viruses that are of
global significance due to their widespread distribution and their
ability to cause a variety of diseases in humans [1]. West Nile virus
(WNV) is a mosquito-borne member of this genus and is the etiologic
agent of West Nile encephalitis. WNV is endemic in parts of Africa,
Australia, Europe, Asia, and the Middle East and has been
responsible for periodic outbreaks of encephalitis in humans and
horses. The introduction of WNV into North America in 1999 and its
rapid spread across the United States into Canada, Mexico, and the
Caribbean identifies this virus as an emerging pathogen of clinical
and economic significance for the Western Hemisphere (reviewed in
[2]). While seroprevalence studies indicate that most WNV infections
of humans are subclinical, clinically apparent infections range from a
febrile illness (West Nile fever) to more severe and potentially fatal
neurologic disease [3]. Currently, no WNV vaccine has been
approved for use in humans and treatment is supportive.
Flaviviruses are small (,50 nm diameter) spherical virions
composed of three structural proteins (envelope (E), premembrane
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stoichiometric threshold for neutralization by binding a small
fraction of accessible epitopes on the virion (low occupancy). In
contrast, epitopes predicted to be poorly exposed may require
nearly complete occupancy to achieve threshold requirements for
neutralization [23]. Furthermore, some epitopes on the virion may
not be accessible to antibody engagement with a stoichiometry
that exceeds the threshold required for neutralization. Thus,
antibodies that recognize such epitopes may neutralize poorly, or
not at all, even at concentrations that permit saturation because
too few antibodies can simultaneously dock on the virion.
Paradoxically, many antibodies that recognize poorly accessible
epitopes on the mature virion still show neutralizing activity in
vitro and in vivo [18,26]. How antibodies engage poorly accessible
epitopes on virions with a stoichiometry that permits neutralization is difficult to reconcile using existing static models of virion
structure and envelope organization. In this study, we investigate
how changes in flavivirus structure associated with virion
maturation impact the neutralizing activity of antibodies to WNV.

Author Summary
West Nile virus (WNV) virions incorporate 180 envelope (E)
proteins that are the primary target of neutralizing
antibodies. As newly formed WNV virions are released
from infected cells, the E proteins undergo a significant
organizational change associated with maturation into an
infectious virus. However, this process is not always
efficient, as populations of infectious WNV include virions
that did not complete the maturation process and may be
heterogeneous with respect to the arrangement of E
proteins on the virion. In this study, we found that
neutralization by antibodies specific for epitopes commonly recognized in vivo is strongly impacted by the
maturation state of WNV. Our studies suggest that
maturation of WNV reduces the accessibility of some, but
not all, epitopes on the virion for antibody binding. Virions
that retain some immature character can be neutralized by
monoclonal antibodies that fail to block infection of
populations of WNV composed solely of mature virions.
Similar results were found using polyclonal human serum
obtained from volunteers of two clinical trials of candidate
WNV vaccines. These studies identify unappreciated
aspects of the antigenic complexity of WNV and highlight
the importance of understanding the heterogenous forms
of WNV that may be introduced into or replicating within
the host.

Results
Neutralization of WNV by antibodies that recognize
poorly accessible determinants
The neutralization potential of an antibody is governed by the
number of sites on the virion available for binding (epitope
accessibility) and the strength of binding (affinity) [23,29,30].
Although molecular modeling studies of the mature virion suggest
that many of the known epitopes on the E protein are poorly
accessible, antibodies to these determinants still neutralize
infection to varying degrees [18,26]. To investigate mechanisms
that govern the potency of antibodies that target poorly accessible
epitopes, high-resolution neutralization profiles were generated for
a group of antibodies that recognize structurally distinct epitopes
on the WNV E protein [17,18] (Fig. S1). Neutralization potency
was estimated for each antibody using a recently described and
validated neutralization assay employing WNV reporter virus
particles (RVPs) [23,31]. RVPs are produced by complementation
of a sub-genomic replicon by expression of the structural proteins
of the virus in trans, allowing infection to be measured as a function
of reporter gene expression [32].
Monoclonal antibodies (mAbs) that bind a highly accessible
determinant on the upper lateral ridge of DIII (DIII-lr) potently
neutralize WNV infection in vitro and exhibit significant
protective capacity in vivo [16–18,23,31]. Dose-response curves
obtained with the DIII-lr-specific mAb E16 were sigmoidal,
relatively steep, and revealed complete neutralization of WNV
RVPs at low concentrations of antibody (Fig. 1a; EC50 0.043 nM)
[23]. In contrast, none of the previously described E-proteinspecific monoclonal antibodies recognizing determinants outside
the DIII-lr were capable of completely blocking infection [18,23]
(Fig. 1b–d). By comparison with E16, dose-response profiles
obtained for most DI- and DII-specific mAbs were relatively flat
and revealed reduced neutralization potency, as illustrated by the
DII fusion loop (DII-fl)-specific mAb E64 [Fig. 1b; EC50 32.2 nM
(n = 2)]. A second pattern was observed for mAbs E121 [Fig. 1c;
EC50 0.69 nM +/2 0.39 (n = 6)] and E53 [Fig. 1d; EC50 1.0 nM
+/2 1.4 (n = 5)] that recognize determinants on the lateral ridge of
DI (DI-lr) and the DII-fl, respectively [18] (Fig. S1). Dose-response
profiles for these antibodies were sigmoidal, but in contrast to
results obtained with the DIII-lr specific mAb E16 (Fig. 1a), did
not completely neutralize even at high concentrations of antibody.
Instead, the level of neutralization plateaued to reveal a fraction of
virions resistant to neutralization at any concentration of antibody
tested. The existence of a fraction of virions resistant to

trimer [6,7]. In this position, prM may prevent conformational
changes that would inactivate the E protein during virion egress
through mildly acidic compartments of the secretory pathway
[8,9]. During transit through the trans-Golgi network (TGN), prM
is cleaved by a cellular furin-like protease resulting in the
formation of a small virion-associated M peptide and the release
of the amino-terminal ‘‘pr’’ portion of the protein [10]. This
required cleavage step promotes a rearrangement of E proteins on
the surface of the virion and the formation of a mature virus
particle. Mature flavivirus virions are relatively smooth and
composed of 90 anti-parallel E protein dimers arranged with
pseudo-icosahedral symmetry [11].
Antibodies are a critical component of host defenses against
flavivirus infection and mediate protection via effector functions
and by direct neutralization of virus (reviewed in [12]). The
primary target for neutralizing antibodies is the E protein,
although antibodies specific for prM have been identified [13–
15]. More than twelve distinct epitopes have been identified on the
surface of the E protein that elicit antibodies characterized by
varying degrees of neutralization potency in vitro and efficacy in
vivo [16–22]. Neutralization of flavivirus infection is a multiple
‘‘hit’’ phenomenon in which virus inactivation occurs once the
number of antibodies bound to a virion exceeds a required
threshold [23,24]. Previous studies with an extremely potent
neutralizing mAb specific for a highly accessible epitope on an
upper lateral surface of WNV DIII (DIII-lr) suggest this threshold
is approximately 30 mAbs [23].
The pseudo-icosahedral arrangement of E proteins on the virion
displays the E protein in three distinct chemical environments
defined by proximity to the two-, three-, or five-fold axes of
symmetry [25]. Epitopes in each of these environments may be
differentially accessible for antibody binding due to steric
constraints imposed by adjacent E proteins on the virus particle
[18,26–28]. As a result, the number of sites available for binding
may differ among structurally distinct epitopes on the virion.
Antibodies that bind highly exposed determinants may exceed the
PLoS Pathogens | www.plospathogens.org
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role of prM in this context is to regulate when E proteins acquire
the capacity to mediate membrane fusion, presumably by
controlling the oligomerization state of the E protein on the
virion. Indeed, genetic studies indicate that furin-mediated
cleavage of prM is required for the release of infectious virions
[33]. However, relatively little is known about the relationship
between the extent of prM cleavage and the acquisition of
infectivity on individual virus particles. Virions may acquire the
potential to infect cells following prM-cleavage-mediated activation of a relatively small fraction of the E proteins on the virion [8–
10,34,35], as observed for the analogous E2 protein of
alphaviruses [36]. Virions containing at least some uncleaved
prM protein are present in bulk virus populations and are
infectious [35,37]. Because epitope accessibility may differ among
individual viruses at intermediate or incomplete stages of
maturation, we investigated the impact of virion maturation on
the neutralization sensitivity of populations of virions containing
different levels of uncleaved prM protein.
WNV RVPs that are produced using our standard complementation conditions (std-RVPs) contain detectable amounts of
uncleaved prM protein (Fig. 2a). This observation was true after
production in several cell lines (BHK-21, 293T, Vero) (Fig. 2a,
data not shown), and agrees with previous studies with infectious
virus [9,32,38–40] or subviral particles [38]. Over-expression of
human furin protease in transfected BHK-21 cells producing
RVPs increased the efficiency of prM cleavage to levels that no
longer allowed detection of unprocessed prM by Western blotting
(furin-RVPs) [37,41]. In contrast, treatment of BHK-21 producer
cells with the weak base ammonium chloride reduced but did not
absolutely block prM cleavage as has been described for other
flaviviruses (NH4Cl-RVPs) [34]. Together, these modifications to
our complementation approach allow for the production of RVPs
that contain virtually no (furin-RVPs), low levels (std-RVPs), or
high levels (NH4Cl-RVPs) of uncleaved prM. RVPs produced
using all three transfection strategies are infectious, as shown by
their capacity to infect Raji-DCSIGNR cells, albeit to differing
degrees (Fig. 2b).

Figure 1. Dose-response profiles of DI/DII antibodies reveal a
fraction of virions resistant to neutralization. Two-fold dilutions
of mAbs E16 (A), E64 (B), E121 (C), and E53 (D) were incubated with
WNV RVPs and used to infect Raji-DCSIGNR cells. The epitope
recognized by each mAb was determined previously and is shown in
each panel: DIII-lr (Domain III lateral ridge), DI-lr (Domain I lateral ridge),
and DII-fl (Domain II fusion loop) [17,18]. Error bars display the standard
error of triplicate infections. Dose-response curves are representative of
2–6 independent assays.
doi:10.1371/journal.ppat.1000060.g001

neutralization even at saturating concentrations of antibody
(,32% +/2 9% and ,19% +/2 7% for E53 and E121,
respectively) implies heterogeneity in antibody accessibility among
individual virions in the population, with some virions unable to
accommodate antibody binding with a stoichiometry sufficient for
neutralization [23].

Manipulating the efficiency of WNV maturation
The arrangement of E proteins on the virion determines the
accessibility of epitopes and thereby influences the neutralization
potency of antibodies. Therefore, the dramatic changes in
conformation and organization of E proteins on the virion during
the flavivirus life cycle have the potential to impact antibody
binding and function [6,7,25]. On immature virions, E proteins
exist in trimeric spikes as heterodimers with the prM protein. The

Virus maturation reduces neutralization of WNV by anti-E
antibodies in an epitope-specific manner
To determine if the cleavage state of prM present on infectious
virions impacts sensitivity to neutralization by anti-E antibodies,

Figure 2. Manipulation of the maturation state of WNV RVPs. (A) RVPs incorporating different amounts of prM protein were produced by
complementation of a BHK-21 cell line that stably propagates a WNV replicon as described in the Materials and Methods. The prM content of each
population was analyzed by SDS-PAGE and Western blotting using E- and prM-specific mAbs. (B) The infectious titer of RVPs was measured by
infecting Raji-DCSIGNR cells with serial four-fold dilutions of virus particles. Infection was measured 48 hours post-infection as a function of luciferase
activity encoded by the replicon. The infectivity of each population of RVPs is shown relative to the genome content of the RVP preparation, which
was measured using a modification of a previously described protocol [38]. Error bars indicate the standard error of triplicate infections. Data are
representative of results obtained with 5 independently prepared stocks of RVPs.
doi:10.1371/journal.ppat.1000060.g002
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Figure 3. Maturation of WNV reduces sensitivity to neutralization by some but not all antibodies. The neutralization sensitivity of std(blue symbols) and furin-RVPs (green symbols) was compared using mAbs that bind structurally distinct epitopes on the E protein. Two-fold dilutions
of the DIII-specific mAbs E16 (A), E24 (B), E49 (C), the DI-specific mAb 121 (D), and the DII-specific mAbs E60 (E) and E53 (F) were incubated with WNV
RVPs and used to infect Raji-DC-SIGNR cells. Error bars display the standard error of triplicate infections. Dose-response curves are representative of at
least 3 independent assays.
doi:10.1371/journal.ppat.1000060.g003

we compared the ability of mAbs to block infection of RVPs
produced using either standard transfection conditions (Fig. 3; stdRVPs, blue circles) or cells that over-express human furin protease
(Fig. 3; furin-RVPs, green circles). Three antibodies directed
against the DIII-lr neutralized infection of both populations of
RVPs with relatively similar potency (Fig. 3a–c; 0.9-, 1.5-, and 4.5fold reduction in neutralization sensitivity of furin-RVPs for mAbs
E16 (p = 0.67), E24 (p = 0.06), and E49 (p = 0.01), respectively). In
contrast, mAbs recognizing determinants on the DI-lr (Fig. 3d,
E121) and DII-fl (Fig. 3e, E60 and Fig. 3f, E53) displayed a
markedly reduced capacity to neutralize infection of completely
mature virions (furin-RVPs). When assayed using furin-RVPs, the
potency of E60 was reduced approximately 95-fold relative to stdRVPs (4.3 +/2 2 nM (n = 8) vs. 408 +/2 113 nM (n = 8) for stdand furin-RVPs respectively (p,0.004)) whereas mAbs E53 (n = 5)
and E121 (n = 6) did not neutralize a significant fraction of furinRVPs.
The reduced ability of mAbs E53, E60, and E121 to neutralize
mature virions was not due to an inability to bind the virus
particle. Antibody-dependent enhancement of infection (ADE)
describes the dramatic increase in infection of Fc-c or complement
receptor-bearing cells in the presence of sub-neutralizing concentrations of antibody or immune sera. Each of these mAbs strongly
enhanced infection of std- and furin-RVPs in cells expressing
activating Fc-c receptors [42] (Fig. 4a, 4d, 4g, respectively).
Consistent with this, both std-RVPs and furin-RVPs bound E53,
E60, and E121 mAbs when either captured directly to plastic (data
not shown), or used in a sandwich ELISA in which virus was
captured using a humanized form of mAb E16 (a DIII-lr antibody
that did not exhibit maturation-dependent differences in binding
or neutralization). Using the latter approach, we measured the
strength of binding of E53, E60, and E121 to WNV RVPs
produced in the presence (furin-RVPs) or absence of furin (stdPLoS Pathogens | www.plospathogens.org

RVPs) (Fig. 4b, 4e, 4h, respectively). All three mAbs bound with
relatively high affinity to both std-RVPs and furin-RVPs, with no
significant differences in the strength of antibody binding to furinRVPs relative to std-RVPs noted ((1.1 fold difference; p = 0.83),
(1.2 fold difference; p = 0.67), and (1.3 fold difference; p = 0.38) for
E53, E60, and E121, respectively).
The ability of the DI- and DII-specific mAbs to bind virions
with relatively high affinity regardless of maturation state appears
to conflict with their modest neutralizing capacity. Integration of
affinity data with the neutralization dose-response curves,
however, reveals that E53, E60, and E121 inhibit WNV infection
only when a large fraction (99%) of accessible epitopes on virions
are bound by antibody (Fig. 4c, 4f, 4i, respectively). The presence
of a fraction of virions in std-RVP populations that remain
infectious even at concentrations of antibody that allow complete
occupancy suggests that a subset of virions do not display these
epitopes at a stoichiometry sufficient to exceed the threshold
required for neutralization [23]. In agreement, the occupancy
requirements of these DI and DII mAbs suggest they bind an
epitope that is not accessible on the average virion in std-RVP
populations at a level that greatly exceeds the threshold
requirements for neutralization [23]. Thus, even a small change
in accessibility can significantly affect the potential for virion
neutralization.

Enhanced neutralization of WNV virions incorporating
uncleaved prM
If the changes in the arrangement of E proteins on virions that
occur during maturation of WNV results in a reduction in the
accessibility of epitopes in DI and DII, we would predict that
populations of less mature virions containing greater amounts of
non-cleaved prM should be more sensitive to neutralization by
these mAbs. To test this hypothesis, WNV RVPs were produced in
4
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Figure 4. Neutralization by antibodies that target poorly accessible determinants occurs at complete occupancy of accessible
epitopes. (A, D, G) Antibody-dependent enhancement of infection (ADE) describes an increase in the efficiency of infection of Fc-receptor bearing
cells in the presence of non-neutralizing quantities of antibody. Std- (blue symbols) and furin-RVPs (green symbols) were mixed with serial four-fold
dilutions of mAb E53 prior to infection of K562 cells. Infection was monitored as a function of GFP expression using flow cytometry. Infection
efficiency is expressed relative to the percentage of K562 cells infected in the absence of antibody (set as 100). Error bars display the standard error of
duplicate infections. (B, E, H) The affinity of mAb binding to RVPs was measured by ELISA using a particle-capture format. Data were analyzed as
described in the Materials in Methods; error bars represent the standard errors of data from duplicate wells. The dotted line indicates the confidence
interval for the regression analysis. (C, F, I) Occupancy requirements for neutralization were estimated by plotting data from mAb dose-response
curves (y-axis) against the percentage of accessible epitopes bound by antibody at each point on the neutralization profile as described previously
[23]. The percentage of accessible epitopes bound by antibody was computed using the affinity data obtained above by solving the equation:
percentage bound = [Ab]/([Ab]+KD). Error bars display the standard error of triplicate infections.
doi:10.1371/journal.ppat.1000060.g004

of DIII that is poorly exposed on mature virions [23]. By
comparison to studies with std-RVPs, dose-response studies with
E22 revealed a reduced capacity to neutralize furin-RVPs,
whereas studies with NH4Cl-RVPs revealed greater neutralizing
activity (Fig. 5c). These results indicate that changes in
neutralization sensitivity associated with maturation can occur
for epitopes throughout the E protein and are not restricted to
those in proximity to regions involved in prM-E protein
interactions.

HEK-293T cells in the presence or absence of exogenous human
furin plasmid, or in the presence of ammonium chloride, which
inhibits prM cleavage. HEK-293T cells were used to produce the
RVPs for these experiments because they support the release of
higher titers of infectious RVPs relative to BHK-21 cells, allowing
production of NH4Cl-RVPs at titers sufficient for neutralization
studies under conditions of antibody excess. Neutralization profiles
for all three populations of RVPs were generated using the
indicated mAbs (Fig. 5). In agreement with experiments using
BHK-derived RVPs, the potency of mAbs that recognize the
highly accessible DIII-lr did not appreciably change when
the proportion of mature and immature virus particles in the
population was manipulated (Fig. 5a). In contrast, the DI- (E121;
Fig. 5b) and DII-specific mAbs (E53; data not shown) were less
effective at neutralizing furin-RVPs, but displayed an increased
capacity to block infection of virions with increased levels of prM
(NH4Cl-RVPs). Neutralization profiles by some DIII-specific
mAbs exhibited a prominent resistant fraction, similar to our
results with E121. E22 binds an epitope on a lower lateral surface
PLoS Pathogens | www.plospathogens.org

Neutralization by polyclonal antibodies in vaccine
recipients is sensitive to the state of WNV maturation
Recent studies indicate that the human humoral immune
response to flavivirus infection is narrower than anticipated, with
antibody specificity focused on determinants in the fusion loop in
DII. B-cell repertoire analysis of three WNV-infected humans
revealed that only 8% of WNV-specific B-cell clones produced
antibodies specific to DIII, whereas almost half produced antibody
that bound determinants in DII [43]. In addition, functional
5
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Figure 5. Neutralization sensitivity of RVPs that retain increased levels of prM. (A–C) The neutralization sensitivity of std- (blue symbols),
furin- (green symbols), and NH4Cl-RVPs (purple symbols) was compared. Two-fold dilutions of the DIII-lr-specific mAb E24 (A), the DI-specific mAb 121
(B), and DIII-specific mAbs E22 (C) were incubated with WNV RVPs and used to infect Raji-DCSIGNR cells. Error bars display the standard error of
triplicate infections. Three independent assays were performed.
doi:10.1371/journal.ppat.1000060.g005

different antigens or using different immunization schedules,
additional studies will be required to understand the factors that
determine the sensitivity of the humoral response to heterogenous
populations of flaviviruses. Together, these studies suggest that the
maturation state of WNV represents an additional layer of
antigenic complexity, with the polyclonal response of some vaccine
recipients directed against epitopes with a reduced capacity to
neutralize mature virions.

studies of the polyclonal response of WNV-infected horses and
humans indicate that the neutralization activity of sera is not
dependent upon antibodies directed against the DIII-lr epitope
[44,45]. Thus, during the natural course of flavivirus infection,
many of the neutralizing antibodies present in the polyclonal
response may be directed against determinants that are modulated
by the maturation state of the virion.
To investigate whether the potency of a polyclonal immune
response is sensitive to the maturation state of WNV, we obtained
serum from participants of two different phase I clinical trials of
candidate WNV vaccines. First, the neutralizing antibody response
in serum of twelve individuals immunized with a DNA vaccine
encoding WNV prM-E was characterized [46,47]. This vaccine
encodes the prM-E proteins of WNV, and is thought to promote
the release of subviral particles in vivo. RVPs that incorporate a
single amino acid substitution in the E protein (T332K) that
abrogates antibody binding to all strongly neutralizing mAbs that
map to the DIII-lr epitope [16,17,23] were used to establish that
the neutralizing response to this vaccine was associated with nonDIII-lr antibodies. Neutralization titers obtained with T332KRVPs were not significantly reduced in any individual when
compared to std-RVPs (Fig. S2a), consistent with prior studies in
WNV infected humans and horses [44,45]. In contrast, in parallel
studies performed with furin-RVPs, we observed a significant
reduction in the capacity of sera from half of the recipients to
neutralize furin-RVPs as compared to std-RVPs (Fig. 6a and S2b).
In fact, some individuals mount a response with very little capacity
to neutralize mature virus (furin-RVPs) (compare Fig. 6a and 6b).
Because the E proteins of subviral particles are arranged with a
different geometry (T = 1) relative to the pseudo-icosahedral
(T = 3) structure of infectious virions, it is possible that the
repertoire of antibodies elicited by this form of vaccination may be
more sensitive to the maturation state of WNV than one elicited
by an infectious virion. Therefore, we also characterized the
polyclonal response of six recipients of a live-attenuated WNV
vaccine. In agreement with the results described above, the
neutralizing antibody response of roughly half the recipients of the
live-attenuated candidate vaccine also displayed a significantly
reduced capacity to neutralize furin-RVPs relative to their potency
against std-RVPs (Fig. S2c). Two of these subjects failed to
neutralize furin-RVPs at all, despite a capacity to neutralize stdRVPs (compare Fig. 6c and 6d). In contrast, sera from two of these
recipients neutralized furin-RVPs at modestly higher titers than
observed with std-RVPs. As the concentrations and specificities of
the individual antibodies that comprise a polyclonal response are
probably dynamic and could differ following vaccination with
PLoS Pathogens | www.plospathogens.org

Discussion
Neutralization of WNV is a ‘‘multiple-hit’’ phenomenon that
requires the simultaneous engagement of the virus particle by as
many as 30 antibody molecules [23,24]. In this regard, the
neutralization potential of an antibody is determined by the
strength of binding and the abundance of its epitope on the virion
(reviewed in [29]). Antibodies that bind the highly accessible DIIIlr epitope can exceed the threshold required for neutralization by
binding a fraction of available epitopes displayed on the virion
[23]. However, many of the epitopes recognized by antibodies
produced following natural infection are not predicted to be
accessible on the fully mature virion due to steric constraints
imposed by the pseudo-icosahedral arrangement and packing of
the E protein [18,26]. Antibodies that recognize poorly exposed
epitopes must bind a larger fraction of sites to exceed the
stoichiometric requirements for neutralization [23]. Consistent
with this, studies with mAbs E53, E60, and E121 which bind two
distinct, poorly exposed epitopes on the E protein (DII-fl and DIlr) indicate that neutralization of WNV infection occurs only when
all (.99%) accessible determinants on the average virion are
engaged by antibody.
For antibodies that bind epitopes requiring virtually complete
occupancy to achieve neutralization, even modest changes in
epitope accessibility can significantly affect the outcome of
antibody binding. While the changes in E protein organization
that define flavivirus maturation provide a mechanism for
regulating the fusion activity of the class II glycoproteins of the
virion [48], a consequence of maturation may be to mask epitopes
recognized by the humoral response. Increasing the efficiency of
prM cleavage (virion maturation) significantly reduces neutralization potency of many antibodies specific for epitopes predicted to
be poorly exposed on the mature virion. This is apparent by
comparing the neutralization profiles of the DI-specific mAb E121
with RVPs containing virtually no (furin-RVPs), low levels (stdRVPs), or high levels (NH4Cl-RVPs) of uncleaved prM. In
contrast, potently neutralizing mAbs specific for a highly accessible
epitope on the DIII-lr (e.g., E16) neutralize WNV RVPs regardless
6
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Figure 6. Polyclonal responses from vaccine recipients are sensitive to WNV maturation. (A–B) Neutralization profiles of the sera of twelve
recipients twelve weeks after receiving a WNV DNA vaccine were obtained using furin-RVPs (green symbols) and a variant incorporating a single
point mutation (T332K) that abrogates the binding of (and neutralization by) antibodies specific for the DIII-lr epitope (T332K: orange symbols)
[17,23]. Neutralization profiles with std-RVPs were obtained previously (blue symbols) [46]. Neutralization studies were performed on Raji-DCSIGNR
cells with RVPs produced in BHK-21 cells. Neutralization potency of sera from two volunteers that were (A; volunteer G) or were not (B; volunteer D)
sensitive to the maturation state of WNV are displayed for all three types of RVPs. (C–D) Neutralization profiles of the sera of six recipients of a liveattenuated WNV vaccine were analyzed using std- and furin-RVPs. Neutralization potency of serum from two volunteers that differ significantly in
their capacity to neutralize furin-RVPs are shown (compare panels C (volunteer FF) and D (volunteer II)). Data for all vaccinated subjects are displayed
in Fig. S2.
doi:10.1371/journal.ppat.1000060.g006

of the amount of prM present. Antibodies specific for poorly
accessible epitopes do not completely lose the capacity to bind
mature virions, nor do they bind with significantly reduced
affinity. Instead, our studies suggest that maturation reduces the
number of antibodies that may simultaneously bind the virion to
levels that do not exceed a required threshold for neutralization
even at full occupancy.
Because the arrangement of E protein on ‘‘partially mature’’
virions that retain uncleaved prM protein has not been resolved by
structural studies, it remains uncertain how prM increases the
accessibility of epitopes that are poorly accessible on the mature
virion. While not observed in our studies, the presence of prM on
virions will likely reduce the binding of some epitopes, as has been
observed by ELISA using DENV and TBE [8,35]. However,
biochemical analyses of bulk virion populations may be limited, as
these methods average the contribution of individual virus
particles without regard to their infectious potential. While none
of the antibodies analyzed in this study bind prM directly, one
potential mechanism for an increased stoichiometry of binding to
prM-containing viruses is an increase in the accessibility of
epitopes on the E proteins when arranged as trimers associated
with prM, relative to their accessibility in the pseudo-icosahedral
mature virion. However, several of the mAbs with altered
neutralization sensitivity recognize the fusion loop, which may
be masked by direct interactions with prM [7]. Alternatively,
changes in E protein epitope accessibility associated with
maturation may reflect dynamic aspects of virion structure that
PLoS Pathogens | www.plospathogens.org

are not evident from existing structural studies. Cryo-EM
reconstructions provide an average structural state of E proteins
on the virion. These static models of E protein arrangement
cannot account for antibody binding to transiently exposed
determinants that result from dynamic and/or lateral movement
among E proteins on the virion. Partially mature virions that
contain uncleaved prM may be more dynamic than mature virus
with respect to the number or stability of alternate structural
conformations that E proteins can attain.
Depending upon the proportion of immature, partially mature,
and mature virions in a population of WNV, the same antibody
may have little, modest, or significant neutralizing activity. From a
technical perspective, maturation state-dependent neutralization
has significant implications for the reproducibility of neutralization
tests among laboratories, and may be important for determining
whether antibodies in a given serum sample are judged as
protective. More importantly, these studies suggest that the
protective capacity of an antibody may depend in part upon the
maturation state of virus delivered through the bite of a mosquito
or released from infected human tissues in vivo. While the
functional contribution of antibodies of different specificities in
sera from infected or vaccinated humans is not yet understood,
humans do produce large numbers of antibodies specific for
determinants outside of the DIII-lr [43,44]. These may exhibit a
significantly reduced potential to neutralize mature WNV. Indeed,
half the recipients of two candidate WNV DNA vaccines evaluated
in this study generated a polyclonal response that was notably less
7
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effective at neutralizing mature virus. Whether response to
immunization with other classes of WNV vaccines, different
immunization schedules, or natural infection will result in
responses more capable of neutralizing all forms of the virus is
of significant interest. Together these studies suggest that a
consequence of maturation of WNV is a reduction in sensitivity to
neutralization by antibodies recognizing specificities that are an
important component of the humoral response to infection and
vaccination. The influence of maturation on the neutralization
sensitivity of WNV identifies an unappreciated functional
consequence for the heterogeneity of prM cleavage in populations
of flaviviruses [8–10,34,35,49], and introduces an additional layer
of complexity into analyses of humoral immunity against WNV.

instructions (Promega, Madison, WI). To relate the infectivity of
each population of RVPs relative to the number of particles in the
supernatant, the RNA content of each stock was measured as
described previously [38].

Neutralization and enhancement of WNV RVP infection

BHK-21 WNIIrep-G/Z, 293T, Vero, Raji-DCSIGNR and
K562 cells were maintained as described previously [23,31].

Neutralization studies were performed using Raji-DCSIGNR
cells as described previously [18,23]. WNV RVP stocks were
diluted and incubated with mAb for 60–120 minutes at room
temperature. Antibody-RVP complexes were then added to preplated cells in triplicate. Percent infection was measured by flow
cytometry at 48 hours after RVP addition. The EC50 of each
antibody was predicted by non-linear regression analysis using a
variable slope. Statistical comparisons of the neutralization
potency of different mAbs were performed using the T-test
(GraphPad Prism 4, GraphPad Software Inc., San Diego CA).
Antibody-dependent enhancement of infection was measured
using K562 cells that express the activating Fc-c receptor CD32a
as described [23].

WNV immune sera

Detection of prM in WNV RVPs by Western blot analysis

Materials and Methods
Cell lines

Neutralization studies were performed on sera obtained from
two WNV vaccine trials sponsored by the NIH. First, sera were
obtained from twelve participants in a single-site, Phase I, openlabel study to examine the safety, tolerability, and immune
response to an investigational recombinant DNA WNV vaccine
encoding prM and E, described in detail elsewhere [46]. Second,
sera from six participants of a Phase I double-blinded, placebocontrolled study to evaluate the safety, infectivity, attenuation and
immunogenicity of a live-attenuated WNV/DENV4 vaccine were
obtained for analysis (A. Durbin, unpublished). These studies and
subsequent analyses were performed in compliance with the
guidelines of The U.S. Department of Health and Human
Services (DHHS), and the protocols were approved by the
respective Institutional Review Boards. Neutralization studies with
WNV-immune sera were performed on Raji-DCSIGNR cells with
RVPs produced in BHK-21 cells as described below.

RVPs were harvested at 48 hours post-transfection, filtered
using a 0.22 mM filter, and concentrated and partially purified by
ultracentrifugation through a 20% sucrose cushion. RVPs were
resuspended in TNE buffer (100 mM Tris, 2 M NaCl, 100 mM
EDTA, pH adjusted to 7.4) and analyzed using SDS-PAGE and
Western blotting. E protein was detected using the mAb E16
(1 mg/ml), whereas prM was detected using a commercial
antibody specific for residues 8–27 of the WNV M protein
(1 mg/ml) (Imgenex, San Diego, CA).

Antibody affinity measurements
Antibody affinity was measured using an indirect ELISA and
WNV RVPs produced in HEK-293T cells. High-protein-binding
plates were coated with a 1 mg/ml humanized mAb E16 overnight
at 4 uC using alkaline conditions. Plates were blocked in blocking
buffer (BB: 1X PBS, 0.05% Tween-20, and 1% BSA) and WNV
RVPs diluted in BB were then bound at room temperature for
2 hours with gentle shaking. Virus particle-coated plates were then
incubated in the presence of serial dilutions of anti-WNV
antibodies under conditions of antibody excess. Bound antibody
was detected using a horseradish peroxidase-conjugated goat antimurine kappa chain antibody. Antibody affinity was estimated
using non-linear regression with a hyperbolic equation that
describes the binding of a ligand to a receptor under conditions
that follow the law of mass action (one-site binding equation;
Bound = ((Bmax)(X)/(KD+X)). Statistical comparisons were made
using the T-test (GraphPad Prism 4).
The occupancy requirements for neutralization by each
antibody were estimated by plotting data from mAb dose-response
curves (y-axis) against the percentage of accessible epitopes bound
by antibody at each concentration of antibody as described
previously [23]. The percentage of accessible epitopes bound by
antibody was computed at each point on the dose-response curve
using the affinity data obtained above by solving the equation:
percent bound = [Ab]/([Ab]+KD).

Production of WNV RVPs
RVPs were produced using methods and constructs described
previously [23,31,41]. For RVPs produced in BHK cells, BHK-21
WNIIrep-G/Z cells were transfected with a plasmid encoding
WNV C-prM-E and an empty pcDNA vector using a 1:3 ratio by
mass (std-RVPs). Std-RVP stocks derived from HEK-293T cells
were produced by transfection with plasmids encoding either the
WNIIrep-G/Z or WNIIrep-REN replicon, C-prM-E, and pcDNA
using a 0.5:1:2.5 ratio. Maturation of RVPs produced in either cell
type was enhanced (furin-RVPs) by including a plasmid encoding
human furin protease in place of the pcDNA vector. To produce
immature RVPs, media from transfected cells was exchanged with
media containing 20 mM ammonium chloride (in phosphate
buffered saline) at 12 hours post-transfection, and again two hours
later. Transfections were performed in T75 flasks using 40 mg of
DNA and Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and
harvested at 48 hours post-transfection. The efficiency of prM
cleavage of populations of RVPs produced in either BHK-21 or
HEK-293T cells was determined by Western blotting as described
below.

Supporting Information

Measuring the infectious titer of WNV RVPs

Figure S1 Maturation of WNV reduces sensitivity to neutralization by some but not all antibodies. Ribbon diagram of the
WNV E protein highlighting residues that form the epitopes
recognized by mAbs used in this study. Domains II, I, and III are
shown as yellow, red, and blue ribbons. Residues on the Domain

The infectious titer of RVP preparations was determined by
infecting Raji-DCSIGNR cells with serial four-fold dilutions of
RVPs in triplicate. Cells were lysed 36–40 hours post-infection
and assayed for luciferase activity according to the manufacturer’s
PLoS Pathogens | www.plospathogens.org
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III lateral ridge (DIII-lr) involved in recognition by mAbs E16,
E24, and E49 are indicated as orange spheres. Epitopes
recognized by E121 (Domain I lateral ridge: DI-lr), E53, and
E60 (both in the Domain II fusion loop: DII-fl) are identified as
yellow, blue, and red spheres, respectively. Overlapping residues
recognized by both E60 and E53 are shown in purple.
Found at: doi:10.1371/journal.ppat.1000060.s001 (0.47 MB TIF)

from six recipients of a single dose, live-attenuated WNV vaccine
six weeks post-vaccination were obtained using furin-RVPs as
described above. The average EC50 obtained is displayed, with
error bars indicating the standard error of 3 independent assays.
* = p,0.05, ** = p,0.01, *** = p,0.005.
Found at: doi:10.1371/journal.ppat.1000060.s002 (0.26 MB TIF)

Figure S2 Polyclonal responses from vaccine recipients are
sensitive to WNV maturation. Neutralization profiles of sera from
twelve recipients of a WNV DNA vaccine twelve weeks postvaccination were obtained using RVPs incorporating the T332K
mutation (A) and furin-RVPs (B). These studies were performed
on Raji-DCSIGNR cells with RVPs produced in BHK-21 cells.
Dose-response curves were obtained and analyzed as described
above using serial three-fold dilutions of sera. The EC50 obtained
with std-, T332K- and furin-RVPs for all volunteers studied is
displayed with error bars indicating the standard error obtained
using 2–4 independent assays. (C) Neutralization profiles of sera

Acknowledgments
The authors thank S. Johnson and S. Burke for the humanized E16
antibody, and both the VRC 302 Clinical Study Team and CIR Clinical
Study Team for their efforts obtaining the clinical material used in this
study.

Author Contributions
Conceived and designed the experiments: SN CJ TP. Performed the
experiments: SN CJ QX JE. Analyzed the data: SN CJ MD TP.
Contributed reagents/materials/analysis tools: JM TO SW AD BG MD.
Wrote the paper: SN MD TP.

References
20. Roehrig JT, Bolin RA, Kelly RG (1998) Monoclonal antibody mapping of the
envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246: 317–328.
21. Roehrig JT, Mathews JH, Trent DW (1983) Identification of epitopes on the E
glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies.
Virology 128: 118–126.
22. Heinz FX, Berger R, Tuma W, Kunz C (1983) A topological and functional
model of epitopes on the structural glycoprotein of tick-borne encephalitis virus
defined by monoclonal antibodies. Virology 126: 525–537.
23. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, et al. (2007)
Stoichiometric requirements for antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host and Microbe 1: 135–146.
24. Della-Porta AJ, Westaway EG (1978) A multi-hit model for the neutralization of
animal viruses. J Gen Virol 38: 1–19.
25. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. (2002)
Structure of dengue virus: implications for flavivirus organization, maturation,
and fusion. Cell 108: 717–725.
26. Stiasny K, Kiermayr S, Holzmann H, Heinz FX (2006) Cryptic properties of a
cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80:
9557–9568.
27. Kaufmann B, Nybakken GE, Chipman PR, Zhang W, Diamond MS, et al.
(2006) West Nile virus in complex with the Fab fragment of a neutralizing
monoclonal antibody. Proc Natl Acad Sci U S A 103: 12400–12404.
28. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, et al. (2005)
Structural basis of West Nile virus neutralization by a therapeutic antibody.
Nature 437: 764–769.
29. Burton DR, Saphire EO, Parren PW (2001) A model for neutralization of viruses
based on antibody coating of the virion surface. Curr Top Microbiol Immunol
260: 109–143.
30. Klasse PJ, Sattentau QJ (2002) Occupancy and mechanism in antibodymediated neutralization of animal viruses. J Gen Virol 83: 2091–2108.
31. Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, et al. (2006) A rapid
and quantitative assay for measuring antibody-mediated neutralization of West
Nile virus infection. Virology 346: 53–65.
32. Khromykh AA, Varnavski AN, Westaway EG (1998) Encapsidation of the
flavivirus kunjin replicon RNA by using a complementation system providing
Kunjin virus structural proteins in trans. J Virol 72: 5967–5977.
33. Elshuber S, Allison SL, Heinz FX, Mandl CW (2003) Cleavage of protein prM is
necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen
Virol 84: 183–191.
34. Randolph VB, Winkler G, Stollar V (1990) Acidotropic amines inhibit
proteolytic processing of flavivirus prM protein. Virology 174: 450–458.
35. Guirakhoo F, Bolin RA, Roehrig JT (1992) The Murray Valley encephalitis
virus prM protein confers acid resistance to virus particles and alters the
expression of epitopes within the R2 domain of E glycoprotein. Virology 191:
921–931.
36. Salminen A, Wahlberg JM, Lobigs M, Liljestrom P, Garoff H (1992)
Membrane fusion process of Semliki Forest virus. II: Cleavage-dependent
reorganization of the spike protein complex controls virus entry. J Cell Biol 116:
349–357.
37. Davis CW, Nguyen HY, Hanna SL, Sanchez MD, Doms RW, et al. (2006) West
Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular
attachment and infection. J Virol 80: 1290–1301.
38. Hanna SL, Pierson TC, Sanchez MD, Ahmed AA, Murtadha MM, et al. (2005)
N-linked glycosylation of west nile virus envelope proteins influences particle
assembly and infectivity. J Virol 79: 13262–13274.

1. Rice CM (1996) Flaviviridae: The Viruses and Their Replication. In: Fields BN,
Knipe PM, Howley PM, editors. Fields Virology. 3rd ed. Philadelphia:
Lippincott-Raven. pp 931–959.
2. Mackenzie JS, Gubler DJ, Petersen LR (2004) Emerging flaviviruses: the spread
and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med
10: S98–109.
3. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, et al. (2005) Virology,
pathology, and clinical manifestations of West Nile virus disease. Emerg Infect
Dis 11: 1174–1179.
4. Mukhopadhyay S, Kuhn RJ, Rossmann MG (2005) A structural perspective of
the flavivirus life cycle. Nat Rev Microbiol 3: 13–22.
5. Mackenzie JM, Westaway EG (2001) Assembly and maturation of the flavivirus
Kunjin virus appear to occur in the rough endoplasmic reticulum and along the
secretory pathway, respectively. J Virol 75: 10787–10799.
6. Zhang Y, Kaufmann B, Chipman PR, Kuhn RJ, Rossmann MG (2007)
Structure of immature West Nile virus. J Virol 81: 6141–6145.
7. Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, et al. (2003) Structures
of immature flavivirus particles. Embo J 22: 2604–2613.
8. Heinz FX, Stiasny K, Puschner-Auer G, Holzmann H, Allison SL, et al. (1994)
Structural changes and functional control of the tick-borne encephalitis virus
glycoprotein E by the heterodimeric association with protein prM. Virology 198:
109–117.
9. Guirakhoo F, Heinz FX, Mandl CW, Holzmann H, Kunz C (1991) Fusion
activity of flaviviruses: comparison of mature and immature (prM-containing)
tick-borne encephalitis virions. J Gen Virol 72 (Pt 6): 1323–1329.
10. Stadler K, Allison SL, Schalich J, Heinz FX (1997) Proteolytic activation of tickborne encephalitis virus by furin. J Virol 71: 8475–8481.
11. Mukhopadhyay S, Kim BS, Chipman PR, Rossmann MG, Kuhn RJ (2003)
Structure of West Nile virus. Science 302: 248.
12. Samuel MA, Diamond MS (2006) Pathogenesis of West Nile Virus infection: a
balance between virulence, innate and adaptive immunity, and viral evasion.
J Virol 80: 9349–9360.
13. Falconar AK (1999) Identification of an epitope on the dengue virus membrane
(M) protein defined by cross-protective monoclonal antibodies: design of an
improved epitope sequence based on common determinants present in both
envelope (E and M) proteins. Arch Virol 144: 2313–2330.
14. Pincus S, Mason PW, Konishi E, Fonseca BA, Shope RE, et al. (1992)
Recombinant vaccinia virus producing the prM and E proteins of yellow
fever virus protects mice from lethal yellow fever encephalitis. Virology 187:
290–297.
15. Colombage G, Hall R, Pavy M, Lobigs M (1998) DNA-based and alphavirusvectored immunisation with prM and E proteins elicits long-lived and protective
immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250:
151–163.
16. Beasley DW, Barrett AD (2002) Identification of neutralizing epitopes within
structural domain III of the West Nile virus envelope protein. J Virol 76:
13097–13100.
17. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, et al. (2005)
Development of a humanized monoclonal antibody with therapeutic potential
against West Nile virus. Nat Med 11: 522–530.
18. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, et al. (2006) Antibody
Recognition and Neutralization Determinants on Domains I and II of West Nile
Virus Envelope Protein. J Virol..
19. Crill WD, Chang GJ (2004) Localization and characterization of flavivirus
envelope glycoprotein cross-reactive epitopes. J Virol 78: 13975–13986.

PLoS Pathogens | www.plospathogens.org

9

May 2008 | Volume 4 | Issue 5 | e1000060

WNV Maturation Affects Neutralization Sensitivity

45. Sanchez MD, Pierson TC, Degrace MM, Mattei LM, Hanna SL, et al. (2007)
The neutralizing antibody response against West Nile virus in naturally infected
horses. Virology 359: 336–348.
46. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, et al. (2007) A West Nile
virus DNA vaccine induces neutralizing antibody in healthy adults during a
phase 1 clinical trial. J Infect Dis 196: 1732–1740.
47. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, et al. (2001) West
Nile virus recombinant DNA vaccine protects mouse and horse from
virus challenge and expresses in vitro a noninfectious recombinant antigen
that can be used in enzyme-linked immunosorbent assays. J Virol 75:
4040–4047.
48. Allison SL, Schalich J, Stiasny K, Mandl CW, Kunz C, et al. (1995) Oligomeric
rearrangement of tick-borne encephalitis virus envelope proteins induced by an
acidic pH. J Virol 69: 695–700.
49. Randolph VB, Stollar V (1990) Low pH-induced cell fusion in flavivirus-infected
Aedes albopictus cell cultures. J Gen Virol 71 (Pt 8): 1845–1850.

39. Elshuber S, Mandl CW (2005) Resuscitating mutations in a furin cleavagedeficient mutant of the flavivirus tick-borne encephalitis virus. J Virol 79:
11813–11823.
40. Kimura T, Ohyama A (1988) Association between the pH-dependent
conformational change of West Nile flavivirus E protein and virus-mediated
membrane fusion. J Gen Virol 69 (Pt 6): 1247–1254.
41. Davis CW, Mattei LM, Nguyen HY, Ansarah-Sobrinho C, Doms RW, et al.
(2006) The location of asparagine-linked glycans on West Nile virions controls
their interactions with CD209 (DC-SIGN). J Biol Chem.
42. Halstead SB (2003) Neutralization and antibody-dependent enhancement of
dengue viruses. Adv Virus Res 60: 421–467.
43. Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, et al. (2006)
Isolation and characterization of human monoclonal antibodies from individuals
infected with West Nile Virus. J Virol 80: 6982–6992.
44. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, et al. (2007) Induction of
epitope-specificneutralizingantibodiesagainstWestNilevirus.JVirol81:11828–11839.

PLoS Pathogens | www.plospathogens.org

10

May 2008 | Volume 4 | Issue 5 | e1000060

